2B30 Stock Chart & Stats
€7.14
-€0.08(-1.17%)
At close: 4:00 PM EDT
€7.14
-€0.08(-1.17%)
Day’s Range― - ―
52-Week Range€4.48 - €9.99
Previous CloseN/A
Volume0.00
Average Volume (3M)14.00
Market Cap
€1.66B
Enterprise Value€1.54B
Total Cash (Recent Filing)€121.75M
Total Debt (Recent Filing)€289.44M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 05, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume44
30 Day Avg. Volume14
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.57Price Target Upside62.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€345.37M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Commercial MomentumBroad-based product growth, led by Recorlev and supported by recovery in Gvoke, indicates improving commercial execution across the portfolio. The raised revenue outlook and strong first-half performance provide a durable foundation for expansion over the next several quarters.
High Gross Margins And Improving Cash GenerationStrong gross profitability and positive free cash flow give Xeris resources to fund commercial activities and development internally. The shift from negative operating and free cash flow in earlier periods suggests improving operating discipline, although continued cash conversion remains important.
Product Protection And Pipeline ExpansionDefending Keveyis intellectual property can help preserve the economics of an established rare-disease product, while XP-8121 offers a potential future growth platform. Together, these efforts support portfolio durability beyond the current commercial products.
Bears Say
Fragile Balance Sheet And Elevated LeverageNegative equity and substantial debt leave Xeris with a limited capital cushion relative to its obligations. This can constrain financial flexibility, increase sensitivity to operating setbacks, and make it harder to fund commercial expansion or pipeline investment without additional financing.
Profitability Remains InconsistentPositive operating profit and strong gross margins have not yet translated into consistent bottom-line earnings. Continued net losses can limit internally generated capital and indicate that operating improvements remain vulnerable to spending levels, product mix, and execution.
Higher Investment And XP-8121 Timing UncertaintyThe commercial expansion and XP-8121 program require materially higher spending before the pipeline can contribute revenue. Uncertainty around trial enrollment and timing could prolong the investment period, pressure near-term profitability, and delay validation of the development strategy.
Xeris Pharmaceuticals News
2B30 FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was €4.48 and its highest was €9.99 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is €1.66B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€0.161 earnings per share for the quarter, missing the consensus estimate of €0.011 by -€0.171.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.03.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,320,310 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -€0.161 in its last earnings report, missing expectations of €0.011. Following the earnings report the stock price went down -4.828%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2B30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.57 (62.11% Upside)
€11.57 (62.11% Upside)
Blogger Sentiment
Bullish
DE:2B30 Sentiment 89%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.71%
12-Months-Change
Fundamentals
Return on Equity
-426.33%
Trailing 12-Months
Asset Growth
23.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
2B30 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.View all DE:2B30 earnings summaries2B30 Stock 12 Month Forecast
Average Price Target
€11.57
▲(62.11% Upside)